ASX Announcement
14 Sep 2026

US OTC Listing Process Launched Following Record FY26

Highlights

- **Audeara has formally commenced the process to establish a US OTCID quotation, to unlock potential US investor access**
- **US-based Viriathus Capital appointed to lead OTCID quotation process and OTC Markets engagement**
- **Follows record FY26 Group revenue of ~$4.45m, including c. $1.56m from North America**
- **Considerable revenue uplift delivered alongside commercial progress across AI audio licensing, hearing-health technology and connected audio products**
- **ASX remains Audeara's primary listing and home market, while OTCID quotation has the potential to provide exposure to US capital markets and participants**
- **No capital raising or new securities are proposed as part of the current process - broadening potential investor access without dilution**
- **Quotation remains subject to application, eligibility review and acceptance by OTC Markets - Proposed listing expected in 6-8 weeks.**

Audeara Limited (ASX: AUA) ("Audeara" or "the Company") is pleased to advise that it has formally commenced the process to establish quotation of its ASX-listed ordinary shares on the OTCID tier of the U.S. Over-the-Counter market (“OTCID”) in the United States.

As part of the development and to expedite the process, Audeara has appointed Viriathus Capital LLC Series ("Viriathus") as its non-exclusive Financial Advisor for an initial three-month engagement. Viriathus will manage the OTCID quotation process, including eligibility review, preparation of the application, liaison with OTC Markets Group and the relevant market maker, and ongoing quotation requirements.

The Company’s broader listing expansion follows a year of record Group revenue and significant commercial progress across its core technology platforms. FY26 revenue increased to approximately $4.45 million, including approximately $1.56 million from North America. AUA Technology contributed approximately $1.68 million in revenue during FY26, and the first two OPTEK customer programs incorporating Audeara's proprietary AI audio technology had progressed to commercial production.

These developments reinforce Audeara's position at the convergence of hearing health, connected hardware, embedded software and AI-enabled audio processing. The Board believes this growing commercial validation strengthens the rationale for broadening access to Audeara among United States technology and healthcare investors through an OTC quotation.

The initiative is designed to provide US-based investors with a more familiar and accessible pathway to trade Audeara securities, while the ASX remains the Company's primary listing. It complements Audeara's existing commercial activities in North America and the Company's growing international profile.

Importantly, the proposed OTCID quotation does not involve a capital raising or the issue of new Audeara securities. The initiative is therefore designed to broaden potential investor access without diluting existing shareholders.

Audeara CEO, James Fielding, commented:

> "FY26 was an important year for Audeara. We delivered record revenue, materially improved operating cash flow and saw our technology increasingly move from development into commercial deployment. At the same time, our business has evolved beyond selling audio hardware — we now operate across hearing health, connected devices, embedded software and AI-enabled audio processing.
>
> "We believe that combination creates an increasingly compelling technology story, and North America is already an important commercial market for Audeara. Broadening access to the Company for US technology and healthcare investors is therefore a logical next step. The ASX remains our home market, while an OTC quotation gives us the opportunity to build a wider international investor audience without issuing new shares as part of the quotation process."

Quotation remains subject to completion of the application process, eligibility review and acceptance by OTC Markets. There is no guarantee that quotation will be approved. Audeara will update the market if and when the quotation is approved and trading is able to commence.

This announcement has been authorised by the board of Audeara Limited.

For more information please visit, audeara.com

CORPORATE ENQUIRIES

Dr James Fielding
Managing Director and Chief Executive Officer

james.fielding@audeara.com

INVESTOR & MEDIA ENQUIRIES

Henry Jordan

Six Degrees Investor Relations
henry.jordan@sdir.com.au

ABOUT AUDEARA

Feel connected, your way.

Audeara Limited (ASX: AUA) is a global hearing health leader specialised in innovative listening solutions for people with hearing challenges.

We are passionate about redefining hearing health, with a particular focus on delivering products that provide world-class tailored listening experiences.

We care about connecting people with experiences that bring them joy - whether that's watching a favourite TV show, FaceTiming family or listening to music with confidence.

All Audeara products are purposefully designed and engineered in Australia with precision detail and state-of-the-art technology. Each product delivers optimum listening experiences to enhance quality of life for people of all ages and abilities.

Audeara sells its products through distributors and resellers in Australia, Europe, Asia and North America, and through e-commerce channels.